LDL cholesterol as a novel risk factor for contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention

Atherosclerosis

Volumn 237, Issue 2, 2014, Pages 453-459

  Liu, Yuan hui ^a,b   Liu, Yong ^b   Chen, Ji yan ^b   Zhou, Ying ling ^b   Chen, Zhu jun ^b   Yu, Dan qing ^b   Luo, Jian fang ^b   Li, Hua long ^b   He, Yi ting ^b   Ye, Piao ^b   Ran, Peng ^b   Guo, Wei ^b   Tan, Ning ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Contrast induced acute kidney injury; Low density lipoprotein cholesterol; Percutaneous coronary intervention

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTRAST INDUCED ACUTE KIDNEY INJURY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPOALBUMINEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; REVASCULARIZATION; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

EID: 84908555083     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.10.022     Document Type: Article

References (41)

1. Mehran R., Aymong E.D., Nikolsky E., Lasic Z., Iakovou I., Fahy M., Mintz G.S., Lansky A.J., Moses J.W., Stone G.W., Leon M.B., Dangas G. Asimple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J.Am. Coll. Cardiol. 2004, 44:1393-1399.
2. Wi J., Ko Y.G., Kim J.S., Kim B.K., Choi D., Ha J.W., Hong M.K., Jang Y. Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart 2011, 97:1753-1757.
3. Stacul F., van der Molen A.J., Reimer P., Webb J.A., Thomsen H.S., Morcos S.K., Almen T., Aspelin P., Bellin M.F., Clement O., Heinz-Peer G. Contrast induced nephropathy: updated ESUR contrast media safety committee guidelines. Eur. Radiol. 2011, 21:2527-2541.
4. Isaacs A., Willems S.M., Bos D., Dehghan A., Hofman A., Ikram M.A., Uitterlinden A.G., Oostra B.A., Franco O.H., Witteman J.C., van Duijn C.M. Risk scores of common genetic variants for lipid levels influence atherosclerosis and incident coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 2013, 33:2233-2239.
5. Miwa K. Low density lipoprotein particles are small in patients with coronary vasospasm. Int. J. Cardiol. 2003, 87:193-201.
6. Wang X.H., Wang F., You S.J., Cao Y.J., Cao L.D., Han Q., Liu C.F., Hu L.F. Dysregulation of cystathionine gamma-lyase (CSE)/hydrogen sulfide pathway contributes to ox-LDL-induced inflammation in macrophage. Cell. Signal 2013, 25:2255-2262.
7. Fenyo I.M., Gafencu A.V. The involvement of the monocytes/macrophages in chronic inflammation associated with atherosclerosis. Immunobiology 2013, 218:1376-1384.
8. Yu J., Han J.L., He L.Y., Feng X.H., Li W.H., Mao J.M., Gao W., Wang G. Low density lipoprotein cholesterol level inversely correlated with coronary flow velocity reserve in patients with Type 2 diabetes. J.Geriatr. Cardiol. 2013, 10:159-164.
9. Keenan T.E., Rader D.J. Genetics of lipid traits and relationship to coronary artery disease. Curr. Cardiol. Rep. 2013, 15:396.
10. Wong P.C., Li Z., Guo J., Zhang A. Pathophysiology of contrast-induced nephropathy. Int. J. Cardiol. 2012, 158:186-192.
11. Ongini E., Impagnatiello F., Bonazzi A., Guzzetta M., Govoni M., Monopoli A., Del S.P., Ignarro L.J. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc. Natl. Acad. Sci. U S A 2004, 101:8497-8502.
12. Wassmann S., Faul A., Hennen B., Scheller B., Bohm M., Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ. Res. 2003, 93:e98-e103.
13. McCullough P.A., Adam A., Becker C.R., Davidson C., Lameire N., Stacul F., Tumlin J. Epidemiology and prognostic implications of contrast-induced nephropathy. Am. J. Cardiol. 2006, 98:5K-13K.
14. Persson P.B., Tepel M. Contrast medium-induced nephropathy: the pathophysiology. Kidney Int. 2006, (Suppl.l):S8-S10.
15. Leoncini M., Toso A., Maioli M., Tropeano F., Villani S., Bellandi F. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS study (protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome). J.Am. Coll. Cardiol. 2014, 63:71-79.
16. Han Y., Zhu G., Han L., Hou F., Huang W., Liu H., Gan J., Jiang T., Li X., Wang W., Ding S., Jia S., Shen W., Wang D., Sun L., Qiu J., Wang X., Li Y., Deng J., Li J., Xu K., Xu B., Mehran R., Huo Y. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J.Am. Coll. Cardiol. 2014, 63:62-70.
17. Ma Y.C., Zuo L., Chen J.H., Luo Q., Yu X.Q., Li Y., Xu J.S., Huang S.M., Wang L.N., Huang W., Wang M., Xu G.B., Wang H.Y. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J.Am. Soc. Nephrol. 2006, 17:2937-2944.
18. Ding F.H., Lu L., Zhang R.Y., Zhu T.Q., Pu L.J., Zhang Q., Chen Q.J., Hu J., Yang Z.K., Shen W.F. Impact of elevated serum glycated albumin levels on contrast-induced acute kidney injury in diabetic patients with moderate to severe renal insufficiency undergoing coronary angiography. Int. J. Cardiol. 2013, 167:369-373.
19. Huang S.S., Huang P.H., Wu T.C., Chen J.W., Lin S.J. Association of serum bilirubin with contrast-induced nephropathy and future cardiovascular events in patients undergoing coronary intervention. PLoS One 2012, 7:e42594.
20. Li W.H., Li D.Y., Han F., Xu T.D., Zhang Y.B., Zhu H. Impact of anemia on contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary interventions. Int. Urol. Nephrol. 2013, 45:1065-1070.
21. Moltrasio M., Cabiati A., Milazzo V., Rubino M., De Metrio M., Discacciati A., Rumi P., Marana I., Marenzi G. B-type natriuretic peptide and risk of acute kidney injury in patients hospitalized with acute coronary syndromes. Crit. Care Med. 2014, 42:619-624.
22. Chen Y.L., Fu N.K., Xu J., Yang S.C., Li S., Liu Y.Y., Cong H.L. Asimple preprocedural score for risk of contrast-induced acute kidney injury after percutaneous coronary intervention. Catheter Cardiovasc Interv. 2014, 83:E8-E16.
23. Dart A.M., Chin-Dusting J.P. Lipids and the endothelium. Cardiovasc Res. 1999, 43:308-322.
24. Hein T.W., Kuo L. LDLs impair vasomotor function of the coronary microcirculation: role of superoxide anions. Circ. Res. 1998, 83:404-414.
25. Morcos S.K., Epstein F.H., Haylor J., Dobrota M. Aspects of contrast media nephrotoxicity. Eur. J. Radiol. 1996, 23:178-184.
26. Goldenberg I., Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ 2005, 172:1461-1471.
27. Treasure C.B., Klein J.L., Weintraub W.S., Talley J.D., Stillabower M.E., Kosinski A.S., Zhang J., Boccuzzi S.J., Cedarholm J.C., Alexander R.W. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N.Engl. J. Med. 1995, 332:481-487.
28. Aurelio A., Durante A. Contrast-induced nephropathy in percutaneous coronary interventions: pathogenesis, risk factors, outcome, prevention and treatment. Cardiology 2014, 128:62-72.
29. Liu Y., Tan N., Zhou Y.L., Chen Y.Y., Chen J.Y., Chen J., Luo J.F. High-sensitivity C-reactive protein predicts contrast-induced nephropathy after primary percutaneous coronary intervention. J.Nephrol. 2012, 25:332-340.
30. Liu Y.H., Liu Y., Tan N., Chen J.Y., Chen J., Chen S.H., He Y.T., Ran P., Ye P., Li Y. Predictive value of GRACE risk scores for contrast-induced acute kidney injury in patients with ST-segment elevation myocardial infarction before undergoing primary percutaneous coronary intervention. Int. Urol. Nephrol. 2014, 46:417-426.
31. Patti G., Ricottini E., Nusca A., Colonna G., Pasceri V., D'Ambrosio A., Montinaro A., Di Sciascio G. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial. Am. J. Cardiol. 2011, 108:1-7.
32. Quintavalle C., Fiore D., De Micco F., Visconti G., Focaccio A., Golia B., Ricciardelli B., Donnarumma E., Bianco A., Zabatta M.A., Troncone G., Colombo A., Briguori C., Condorelli G. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 2012, 126:3008-3016.
33. Liu Y.H., Liu Y., Duan C.Y., Tan N., Chen J.Y., Zhou Y.L., Li L.W., He P.C. Statins for the prevention of contrast-induced nephropathy after coronary angiography/percutaneous interventions: a meta-analysis of randomized controlled trials. J.Cardiovasc Pharmacol. Ther. 2014 Sep 5, pii: 1074248414549462. (Epub ahead of print).
34. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.J., Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Glynn R.J. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N.Engl. J. Med. 2008, 359:2195-2207.
35. Luvai A., Mbagaya W., Hall A.S., Barth J.H. Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease. Clin. Med. Insights Cardiol. 2012, 6:17-33.
36. Seeliger E., Sendeski M., Rihal C.S., Persson P.B. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur. Heart J. 2012, 33:2007-2015.
37. Tawfik M.K., Ghattas M.H., Abo-Elmatty D.M., Abdel-Aziz N.A. Atorvastatin restores the balance between pro-inflammatory and anti-inflammatory mediators in rats with acute myocardial infarction. Eur. Rev. Med. Pharmacol. Sci. 2010, 14:499-506.
38. Beg S.A., Hansen-Schwartz J.A., Vikman P.J., Xu C.B., Edvinsson L.I. ERK1/2 inhibition attenuates cerebral blood flow reduction and abolishes ET(B) and 5-HT(1B) receptor upregulation after subarachnoid hemorrhage in rat. J.Cereb. Blood Flow. Metab. 2006, 26:846-856.
39. Tsai T.T., Patel U.D., Chang T.I., Kennedy K.F., Masoudi F.A., Matheny M.E., Kosiborod M., Amin A.P., Messenger J.C., Rumsfeld J.S., Spertus J.A. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary Interventions: Insights from the NCDR Cath-PCI Registry. JACC Cardiovasc Interv. 2014, 7:1-9.
40. Marenzi G., Lauri G., Assanelli E., Campodonico J., De Metrio M., Marana I., Grazi M., Veglia F., Bartorelli A.L. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J.Am. Coll. Cardiol. 2004, 44:1780-1785.
41. Senoo T., Motohiro M., Kamihata H., Yamamoto S., Isono T., Manabe K., Sakuma T., Yoshida S., Sutani Y., Iwasaka T. Contrast-induced nephropathy in patients undergoing emergency percutaneous coronary intervention for acute coronary syndrome. Am. J. Cardiol. 2010, 105:624-628.